Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

Enveric Biosciences Inc. - news published 259 - readings 4.450

BACK

Enveric Biosciences Inc.

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

Press Releases Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders By wpengine February 21, 2024 No Comments Novel compounds protected under Enveric's intellectual property portfolio provide potential licensing opportunities and non-dilutive revenue streams. CAMBRIDGE, Mass. - Enveric Bioscien ...

21.02.2024

Enveric Biosciences Inc.

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders - Form 8-K

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders Novel compounds protected under Enveric's intellectual property portfolio provide potential licensing opportunities and non-dilutive revenue streams. CAMBRIDGE, Mass., February 21, 2024 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" ...

21.02.2024

Enveric Biosciences Inc.

Failure to Satisfy Listing Rule - Form 8-K

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 6, 2024, the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") notified Enveric Biosciences, Inc. (the "Company") that based on the Staff's review of materials submitted by the Company ...

09.02.2024

Enveric Biosciences Inc.

Supplemental Prospectus - Form 424B3

PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-276473 Enveric Biosciences Inc. 2,244,000 Shares of Common Stock This prospectus relates to the resale of up to 2,244,000 shares of Enveric Biosciences, Inc. (the "Company," "we," or "us") common stock, par value $0.01 per share, by the selling stockholders named in this prospectus o ...

24.01.2024

Enveric Biosciences Inc.

Notice of Effectiveness - Form EFFECT

Notice of Effectiveness UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Notice of Effectiveness Effectiveness Date: January 22, 2024 4:30 P.M. Form: S-3 CIK: 0000890821 Company Name: Enveric Biosciences, Inc. File Number: 333-276473 Attachments Original Link Original Document Permalink Disclaimer Enveric Biosciences Inc. published this content on 22 Jan ...

23.01.2024

Enveric Biosciences Inc.

Registration Statement - Specified Transactions - Form S-3

As Filed with the Securities and Exchange Commission on January 11, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Enveric Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 95-4484725 (State or other jurisdiction of incorporation ...

11.01.2024

Enveric Biosciences Inc.

Costs Associated with Exit/Disposal - Form 8-K

Item 2.05 Costs Associated with Exit or Disposal Activities. On January 8, 2024, the Enveric Biosciences, Inc. (the " Company " or " Enveric ") committed to a reduction in force (the " RIF ") that is expected to result in the termination of approximately seven positions, representing approximately 50% of the Company's global workforce. The Company ...

08.01.2024

Enveric Biosciences Inc.

Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series

Press Releases Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series By wpengine January 3, 2024 No Comments Enveric to initiate preclinical development of EB-003 in 2024 in preparation for IND submission CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnol ...

03.01.2024

Enveric Biosciences Inc.

Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series - Form 8-K

Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series Enveric to initiate preclinical development of EB-003 in 2024 in preparation for IND submission CAMBRIDGE, Mass., January 3, 2024 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the developme ...

03.01.2024

Enveric Biosciences Inc.

Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market - Form 8-K

Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market CAMBRIDGE, Mass., December 29, 2023 (BUSINESS WIRE) - Enveric Biosciences (NASDAQ: ENVB ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small- ...

29.12.2023

Enveric Biosciences Inc.

Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market

Press Releases Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market By wpengine December 29, 2023 No Comments CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel ...

29.12.2023

Enveric Biosciences Inc.

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series

Press Releases Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series By wpengine December 28, 2023 No Comments Enveric to initiate preclinical development of EB-003 in 2024 in preparation for IND submission CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the deve ...

28.12.2023

Enveric Biosciences Inc.

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series - Form 8-K

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series Enveric to initiate preclinical development of EB-003 in 2024 in preparation for IND submission CAMBRIDGE, Mass., December 28, 2023 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic smal ...

28.12.2023

Enveric Biosciences Inc.

Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373

Press Releases Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373 By wpengine December 27, 2023 No Comments The ongoing GLP Safety and Toxicology Program of EB-373 is thus far proceeding on time with favorable results CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a ...

27.12.2023

Enveric Biosciences Inc.

Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373 - Form 8-K

Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373 The ongoing GLP Safety and Toxicology Program of EB-373 is thus far proceeding on time with favorable results CAMBRIDGE, Mass., December 27, 2023 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to th ...

27.12.2023

Enveric Biosciences Inc. - news published 259 - readings 4.450

Enveric Biosciences Inc.

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

Enveric Biosciences Inc.

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders - Form 8-K

Enveric Biosciences Inc.

Failure to Satisfy Listing Rule - Form 8-K

Enveric Biosciences Inc.

Supplemental Prospectus - Form 424B3

Enveric Biosciences Inc.

Notice of Effectiveness - Form EFFECT

Enveric Biosciences Inc.

Registration Statement - Specified Transactions - Form S-3

Enveric Biosciences Inc.

Costs Associated with Exit/Disposal - Form 8-K

Enveric Biosciences Inc.

Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series

Enveric Biosciences Inc.

Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series - Form 8-K

Enveric Biosciences Inc.

Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market - Form 8-K

Enveric Biosciences Inc.

Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market

Enveric Biosciences Inc.

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series

Enveric Biosciences Inc.

Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series - Form 8-K

Enveric Biosciences Inc.

Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373

Enveric Biosciences Inc.

Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373 - Form 8-K

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member